Dr. Grey AI

Eptifibatide (Integrilin)

Peptide

Eptifibatide is a synthetic cyclic heptapeptide GP IIb/IIIa inhibitor that blocks platelet aggregation. FDA-approved 1998 for ACS and PCI. PURSUIT Phase 3 (n=10,948): 1.5% absolute reduction in death/MI/refractory ischemia at 30 days (14.2% vs 15.7%, P=0.04). ESPRIT: 37% relative reduction in death/MI/TVR at 6 months with coronary stenting. High-risk medication per ISMP. SAFETY: Increased bleeding risk (major bleeding 1.3% vs 0.4% in ESPRIT), thrombocytopenia (0.2%).

Quick Answer

What it is

Eptifibatide is a synthetic cyclic heptapeptide GP IIb/IIIa inhibitor that blocks platelet aggregation. FDA-approved 1998 for ACS and PCI.

Key findings

  • Grade A: Death/MI/Refractory Ischemia (Acute Coronary Syndrome (ACS))
  • Grade A: Death/MI After PCI Stenting (Percutaneous Coronary Intervention)
  • Grade A: Major Bleeding (Acute Coronary Syndrome (ACS))

Safety

  • High-risk medication per ISMP.
  • SAFETY: Increased bleeding risk (major bleeding 1.3% vs 0.4% in ESPRIT), thrombocytopenia (0.2%).
  • 1.5% absolute risk reduction.
⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Eptifibatide (Integrilin)

Quick Facts: Eptifibatide (Integrilin)

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:7
  • Grade A Findings:3
  • Grade B Findings:3
  • Key Effect:Acute Coronary Syndrome (ACS)
A3
B3
C0
D1
2 conditions · 7 outcomes

Detailed Outcomes

|
A
Death/MI/Refractory Ischemia
PURSUIT (n=10,948): Composite endpoint 14.2% vs 15.7% placebo at 30 days (P=0.04). 1.5% absolute risk reduction. Benefit apparent by 96 hours. NNT=67 to prevent one event.
small↓Improves
A
Major Bleeding
SAFETY CONCERN: ESPRIT: Major bleeding 1.3% vs 0.4% placebo (P=0.027). PURSUIT: 2.1% vs 1.3%. Most bleeding at femoral access sites, mild. No increase in hemorrhagic stroke. ISMP high-risk medication.
small↑Worsens
B
Thrombocytopenia
SAFETY CONCERN: Significant thrombocytopenia (<20,000/ÎĽL) in 0.2% of patients in ESPRIT. Platelet monitoring recommended. Generally reversible upon discontinuation.
small↓Worsens
A
Death/MI After PCI Stenting
ESPRIT (n=2,064): Death/MI/TVR 7.5% vs 11.5% at 6 months (HR 0.63, P=0.002). MI reduced at 48h from 9% to 5.4% (P=0.0015). 37% relative risk reduction. Double-bolus regimen.
moderate↓Improves
B
Cardiac Protection
19 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
B
Safety/Tolerability
15 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
D
Blood Pressure
2 human trials support this finding. Human clinical trial data available.
small↓Improves

Research Citations (48)

Safety and efficacy of adjunctive tirofiban and eptifibatide in acute ischemic stroke: A systematic review and meta-analysis.
(2026)
PMID: 41500359
Eptifibatide as an adjuvant therapy to thrombolysis versus thrombolysis alone in stroke management: a systematic review and meta-analysis of randomized controlled trials.
(2025)
PMID: 40544389
A Double-Blinded Randomized Controlled Trial Comparing Eptifibatide Bolus Only Versus Bolus Plus Infusion In Patients Undergoing Primary Percutaneous Coronary Intervention For ST-Elevation Myocardial Infarction.
(2023)
PMID: 36737382
Intracoronary eptifibatide with vasodilators to prevent no-reflow in diabetic STEMI with high thrombus burden. A randomized trial.
(2022)
PMID: 35039226
Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies.
(2022)
PMID: 34780001
Efficacy and Safety of Abbreviated Eptifibatide Treatment in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
(2021)
PMID: 33065082
Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects.
(2020)
PMID: 31197974
Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice.
(2020)
PMID: 32721916
Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Activating Antiplatelet Antibodies.
(2020)
PMID: 32483771
Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS)-a randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacy.
(2019)
PMID: 31488213

Related Peptides

Bivalirudin

Peptide

1 shared condition · 8 outcomes

Bivalirudin is a synthetic 20-amino acid peptide derived from hirudin (leech anticoagulant) that directly inhibits thrombin. FDA-approved 2000 for PCI anticoagulation, including patients with HIT/HITTS. A-GRADE evidence: HORIZONS-AMI showed reduced major bleeding (4.9% vs 8.3% vs heparin+GPI). Over 25,000 patients studied across REPLACE-2, ACUITY, and HORIZONS-AMI trials. B-GRADE for mortality reduction (driven by bleeding reduction). SAFETY CONCERN: Increased acute stent thrombosis within 24h (1.3% vs 0.3% in HORIZONS-AMI) - mitigated by post-PCI infusion. ESC downgraded to Class IIb in 2018. PRESCRIPTION ONLY - catheterization lab setting.